Huluwa Pharmaceutical Group Focuses on Innovation in Pediatric Medicines and Ranks Among the "2025 Top 100 Chinese Chemical Pharmaceutical R&D Enterprises"

Recently, the "2025 PDI Pharmaceutical R&D & Innovation Conference and China Top 100 Pharmaceutical R&D Rankings Release Conference", jointly organized by Yaozh.com, CNS International Communication Group, and China Pharmaceuticals journal, was held in Chongqing. A series of rankings were announced at the conference. Thanks to its sustained R&D investment and innovation achievements, Huluwa Pharmaceutical Group ranked among the "2025 Top 100 Chinese Chemical Pharmaceutical R&D Enterprises", placing 61st.

 Huluwa Pharmaceutical has adopted a dual-track approach of independent R&D and collaborative R&D, establishing a national-level postdoctoral research workstation, the Hainan Provincial Engineering Research Center for Traditional Chinese Medicine Preparations, and a Joint R&D Laboratory for Pediatric and Southern Traditional Chinese Medicine. Through the modern development of classic renowned medicines and traditional formulas, the company has secured a leading position in the fields of pediatric medicine and traditional Chinese medicine, while continuously strengthening its strategic presence in the chemical pharmaceuticals sector. From 2024 to 2025, the company obtained a cumulative total of 20 production approvals (covering 29 specifications) and 3 clinical trial approvals, spanning therapeutic areas including respiratory, digestive, and neuropathic pain. This inclusion in the ranking reflects the company's development achievements in extending from traditional Chinese medicine into innovative chemical pharmaceuticals.

As one of the leading enterprises in pediatric pharmaceuticals, Huluwa Pharmaceutical Group will continue to strengthen innovation in pediatric drugs and safeguard the safety of pediatric medication in China.